← FDA Drug Approvals (Drugs@FDA)

LISRAYA

NDA · New Drug Application · Sponsor: PRIOVANT THERAP · Approved 2026-08-27

Drug application

FDA Application #

NDA220106

Application type

New Drug Application

Brand name

LISRAYA

Generic name

BREPOCITINIB

Active ingredients

BREPOCITINIB TOSYLATE

Dosage form

TABLET

Route

ORAL

Marketing status

Prescription

Sponsor

PRIOVANT THERAP

Manufacturer

Priovant Therapeutics, Inc.

First approval

2026-08-27

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown